Drug
MGN1703
MGN1703 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
2
50%
Ph phase_2
2
50%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(3)
Detailed Status
Completed3
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 22 (50.0%)
Trials by Status
completed375%
active_not_recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
active_not_recruitingphase_1
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
NCT02668770
completedphase_2
Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC
NCT02200081
completedphase_1
Toll-like Receptor 9 Agonist Treatment in Chronic HIV-1 Infection
NCT02443935
completedphase_2
Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma
NCT01208194
Clinical Trials (4)
Showing 4 of 4 trials
NCT02668770Phase 1
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
NCT02200081Phase 2
Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC
NCT02443935Phase 1
Toll-like Receptor 9 Agonist Treatment in Chronic HIV-1 Infection
NCT01208194Phase 2
Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4